The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent
Philadelphia, Pennsylvania -
Newsfile Corp. - March 6, 2025 - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell...
Read more: Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical...